JP2010535816A - ヘテロアリールアミド類似体 - Google Patents

ヘテロアリールアミド類似体 Download PDF

Info

Publication number
JP2010535816A
JP2010535816A JP2010520343A JP2010520343A JP2010535816A JP 2010535816 A JP2010535816 A JP 2010535816A JP 2010520343 A JP2010520343 A JP 2010520343A JP 2010520343 A JP2010520343 A JP 2010520343A JP 2010535816 A JP2010535816 A JP 2010535816A
Authority
JP
Japan
Prior art keywords
alkyl
indole
pyrimidin
carboxamide
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2010520343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535816A5 (xx
Inventor
バクサバッチャラム・ラジャゴパル
イール・デイビッド・シー
キャピトスティ・スコット・エム
ウストロウ・デイビッド・ジェイ
ユアン・ジュン
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2010535816A publication Critical patent/JP2010535816A/ja
Publication of JP2010535816A5 publication Critical patent/JP2010535816A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010520343A 2007-08-10 2008-08-11 ヘテロアリールアミド類似体 Ceased JP2010535816A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95525007P 2007-08-10 2007-08-10
PCT/US2008/072760 WO2009023623A1 (en) 2007-08-10 2008-08-11 Heteroaryl amide analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014238138A Division JP2015110566A (ja) 2007-08-10 2014-11-25 ヘテロアリールアミド類似体

Publications (2)

Publication Number Publication Date
JP2010535816A true JP2010535816A (ja) 2010-11-25
JP2010535816A5 JP2010535816A5 (xx) 2011-09-29

Family

ID=40351102

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010520343A Ceased JP2010535816A (ja) 2007-08-10 2008-08-11 ヘテロアリールアミド類似体
JP2014238138A Pending JP2015110566A (ja) 2007-08-10 2014-11-25 ヘテロアリールアミド類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014238138A Pending JP2015110566A (ja) 2007-08-10 2014-11-25 ヘテロアリールアミド類似体

Country Status (14)

Country Link
EP (1) EP2185560A4 (xx)
JP (2) JP2010535816A (xx)
KR (1) KR20100066422A (xx)
CN (1) CN101778850A (xx)
AU (1) AU2008286946B2 (xx)
BR (1) BRPI0812594A2 (xx)
CA (1) CA2691512A1 (xx)
CO (1) CO6251319A2 (xx)
EA (1) EA020332B1 (xx)
IL (1) IL202550A0 (xx)
NZ (1) NZ582056A (xx)
SG (1) SG183699A1 (xx)
UA (1) UA99729C2 (xx)
WO (1) WO2009023623A1 (xx)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504086A (ja) * 2012-01-20 2015-02-05 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
JP2015522619A (ja) * 2012-07-17 2015-08-06 武田薬品工業株式会社 ５ｈｔ３受容体拮抗薬
JP2016504995A (ja) * 2012-12-18 2016-02-18 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP2016508967A (ja) * 2012-12-12 2016-03-24 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP2016510325A (ja) * 2013-01-22 2016-04-07 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
JP2016515135A (ja) * 2013-03-14 2016-05-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７モジュレータ
US10329306B2 (en) 2014-09-29 2019-06-25 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2243772E (pt) * 2009-04-14 2012-03-28 Affectis Pharmaceuticals Ag Novos antagonistas de p2x7r e sua utilização
WO2012110190A1 (en) * 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
KR101995088B1 (ko) 2011-07-22 2019-07-02 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7
CA2900302C (en) 2013-02-19 2018-07-03 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
JP6467404B2 (ja) 2013-03-14 2019-02-13 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７モジュレーター
CN105636646B (zh) * 2013-07-17 2017-12-19 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
JP6506833B2 (ja) 2014-08-06 2019-04-24 ファイザー・インク イミダゾピリダジン化合物
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
EP3233841A1 (en) * 2014-12-15 2017-10-25 Merck Patent GmbH Indole and azaindoles derivatives and their use in neurodegenerative diseases
JP6462493B2 (ja) 2015-05-29 2019-01-30 株式会社デンソー 進入判定装置、進入判定方法
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物
US20200102303A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
AU2019349962A1 (en) 2018-09-28 2021-03-18 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
MX2022011902A (es) 2020-03-26 2023-01-04 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa.
WO2022062991A1 (zh) * 2020-09-22 2022-03-31 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5277060A (en) * 1975-12-19 1977-06-29 Hoechst Ag Basic substituted indole derivatives and preparation thereof
JPS58159459A (ja) * 1981-08-08 1983-09-21 カリ−ヒエミ−・フアルマ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング １―フェニル―２―アミノカルボニルインドール化合物および該化合物を含有する抗不整脈剤
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
WO2003016254A1 (fr) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
WO2006100208A1 (en) * 2005-03-21 2006-09-28 N.V. Organon 1-benzylindole-2-carboxamide derivatives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2931323A1 (de) * 1979-08-02 1981-02-26 Kali Chemie Pharma Gmbh Neue n-aminoalkylindol-derivate und ihre salze
TW229140B (xx) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
RU2225397C2 (ru) * 1997-12-24 2004-03-10 Авентис Фарма Дойчланд Гмбх Производные индола как ингибиторы фактора Ха
AU774526B2 (en) * 1999-04-09 2004-07-01 Astrazeneca Ab Adamantane derivatives
AU770600B2 (en) * 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
EP1310488A4 (en) * 2000-08-09 2005-08-10 Mitsubishi Pharma Corp CONDENSED BICYCLIC AMIDE COMPOUNDS AND MEDICAL USES THEREOF
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
SI1549638T1 (sl) * 2002-10-03 2008-02-29 Hoffmann La Roche Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk)
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
WO2004056768A2 (en) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
MX2008010671A (es) * 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5277060A (en) * 1975-12-19 1977-06-29 Hoechst Ag Basic substituted indole derivatives and preparation thereof
JPS58159459A (ja) * 1981-08-08 1983-09-21 カリ−ヒエミ−・フアルマ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング １―フェニル―２―アミノカルボニルインドール化合物および該化合物を含有する抗不整脈剤
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
WO2003016254A1 (fr) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif
WO2006100208A1 (en) * 2005-03-21 2006-09-28 N.V. Organon 1-benzylindole-2-carboxamide derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5011010489; ＲＯＭＡＧＮＯＬＩ: 'ＲＥＣＥＮＴ　ＰＲＯＧＲＥＳＳ　ＩＮ　ＴＨＥ　ＤＩＳＣＯＶＥＲＹ　ＯＦ　ＡＮＴＡＧＯＮＩＳＴＳ　ＡＣＴＩＮＧ　ＡＴ　Ｐ２Ｘ７　ＲＥＣＥＰＴＯＲ' ＥＸＰＥＲＴ　ＯＰＩＮＩＯＮ　ＯＮ　ＴＨＥＲＰＥＵＴＩＣ　ＰＡＴＥＮＴＳ Ｖ１５　Ｎ３, 2005, Ｐ２７１-２８７ *
JPN6013030148; ＨＹＮＥＳ，Ｊ．　ｅｔ　ａｌ: 'Ｃ-３　Ａｍｉｄｏ-Ｉｎｄｏｌｅ　ｃａｎｎａｂｉｎｏｉｄ　ｒｅｃｅｐｔｏｒ　ｍｏｄｕｌａｔｏｒｓ' Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ　Ｌｅｔｔｅｒｓ Ｖｏｌ．１２，　Ｎｏ．１７, 2002, ｐ．２３９９-２４０２ *
JPN6013030149; ＧＩＡＲＤＩＮＡ，Ｇ．Ａ．　ｅｔ　ａｌ: 'Ｒｅｐｌａｃｅｍｅｎｔ　ｏｆ　ｔｈｅ　ｑｕｉｎｏｌｉｎｅ　ｓｙｓｔｅｍ　ｉｎ　２-ｐｈｅｎｙｌ-４-ｑｕｉｎｏｌｉｎｅｃａｒｂｏｘａｍｉｄｅ　ＮＫ-３　ｒｅｃｅｐｔｏｒ　ａｎｔａｇｏｎｉｓｔｓ' Ｆａｒｍａｃｏ Ｖｏｌ．５４，　Ｎｏ．６, 1999, ｐ．３６４-３７４ *
JPN6013030150; ＫＯＳＴ，Ａ．Ｎ．　ｅｔ　ａｌ: 'Ｒｏｔａｔｉｏｎａｌ　ｄｉｓｐｅｒｓｉｏｎ　ｏｆ　ｉｎｄｏｌｅｃａｒｂｏｘｙｌｉｃ　ａｃｉｄ　ａｍｉｄｅｓ' Ｚｈｕｒｎａｌ　Ｏｂｓｈｃｈｅｉ　Ｋｈｉｍｉｉ Ｖｏｌ．３８，　Ｎｏ．８, 1968, ｐ．１７６２-１７６５ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504086A (ja) * 2012-01-20 2015-02-05 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
JP2015522619A (ja) * 2012-07-17 2015-08-06 武田薬品工業株式会社 ５ｈｔ３受容体拮抗薬
JP2016040278A (ja) * 2012-07-17 2016-03-24 武田薬品工業株式会社 ５−ｈｔ３受容体拮抗薬
US10407443B2 (en) 2012-07-17 2019-09-10 Takeda Pharmaceutical Company Limited 5-HT3 receptor antagonists
JP2016508967A (ja) * 2012-12-12 2016-03-24 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP2016504995A (ja) * 2012-12-18 2016-02-18 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP2016510325A (ja) * 2013-01-22 2016-04-07 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
JP2016515135A (ja) * 2013-03-14 2016-05-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７モジュレータ
US10329306B2 (en) 2014-09-29 2019-06-25 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide

Also Published As

Publication number Publication date
CA2691512A1 (en) 2009-02-19
AU2008286946A1 (en) 2009-02-19
JP2015110566A (ja) 2015-06-18
IL202550A0 (en) 2010-06-30
EA020332B1 (ru) 2014-10-30
EA200971085A1 (ru) 2010-06-30
CN101778850A (zh) 2010-07-14
BRPI0812594A2 (pt) 2015-06-23
UA99729C2 (xx) 2012-09-25
WO2009023623A1 (en) 2009-02-19
EP2185560A4 (en) 2011-10-05
SG183699A1 (en) 2012-09-27
NZ582056A (en) 2012-08-31
KR20100066422A (ko) 2010-06-17
AU2008286946B2 (en) 2013-11-21
CO6251319A2 (es) 2011-02-21
EP2185560A1 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
JP2010535816A (ja) ヘテロアリールアミド類似体
JP5813734B2 (ja) ５員複素環アミドおよび関連化合物
US20120190680A1 (en) Heteroaryl Amide Analogues
JP2010523668A (ja) Ｐ２ｘ７拮抗薬としてのヘテロアリールアミド類似体
JP2010510987A (ja) ヘテロアリールアミド誘導体
WO2009108551A2 (en) Heteroaryl amide analogues
WO2007140383A2 (en) Spirocyclic sulfonamides and related compounds
WO2008002849A2 (en) Aryl sulfones
Ihle et al. Heteroaryl amide analogues as P2X7 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110810

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141125

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150107

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150303

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20150728